Novo Nordisk warns of layoffs as pressure mounts
Novo Nordisk is waiting for the ongoing competition from the imitating versions of Wegovy Obesity, which broke box office records this year, and may face dismissal while fighting with increasing pressure from the Main US rival Eli Lilly.
Novo is the most valuable company in Europe, which is worth $ 650 billion (A1.0 trillion) for Wegovy’s explosive sales last year, and has a very important understanding of the drug has lost its market share and especially in the United States, the sales growth in the United States.
In part, he warned that this year, because of compounds that were allowed to perform imitating drugs based on the same materials due to famine, he warned much slower growth this year.
Last week, Novo deleted full -year sales and profit forecasts from the market value of $ 95 billion (A146 billion).
Stocks fell 3.4 percent in the afternoon of Wednesday.
The slide is a big and sudden turn for the company, one of the hottest investment stories in the world.
Now the company follows potential cost -lowering measures.
Danish Publisher
“When you need to set a company, there are some areas where less people, some of them should be smaller.”
Authorized, any decision about the dismissal on Thursday, the company’s veteran Maziar Mazi Dustdar’ın CEO’un in the hands of the CEO, he added.
In a call for a media, Jorgensen said Wegovy’s market of imitating versions of the drug class known as the GLP-1 receptor agonists were “equal to our business ve and that the compound versions of Wegovy were sold at a much lower price point”.
In May, the company said that after the US Food and Pharmaceutical Administration entered into force on May 22 after the Wegovy leaned on the compound copies of Wegovy, it expects most of the US patients using compound GLP-1 drugs to pass to branded treatments and expects the wind of compounds in the third quarter.
However, Munk Knudsen, the Chief of Finance, said on Wednesday that more than one million US patients still use compound GLP-1s and that novo’s dropped appearance did not assume a decrease in the compound ”.
“The obesity market is variable, Kn Knudsen said to the analysts when asked what conditions the company could see negatively under the conditions of the last six months of the year.
Knudsen reiterated that the company followed many strategies, including cases against merger pharmacies to stop illegal mass compounds.
Jorgensen said the company was the latest US prescription data for Wegovy.
The drug was passed by Zepbound in terms of US recipes earlier this year, while this bullet narrowed last month.
Novo said Wegovy’s second quarter sales have increased by 36 percent in the US and a year ago in markets outside the United States.
Wegovy’s US pricing remained constant in the quarter, while the company said that he expects a deeper erosion in the US market in the second half due to higher discounts and discounts for insurance companies, as well as expected sales from the cash payment channel.
Australian Associated Press is a beating heart of Australian news. AAP has been the only independent national Newswire of Australia and has been providing reliable and fast news content to the media industry, the government and the corporate sector for 85 years. We inform Australia.
